Fulgent Genetics (FLGT) Scheduled to Post Quarterly Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, May 3rd. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Fulgent Genetics has set its FY24 guidance at -$1.05 EPS and its FY 2024 guidance at -1.050–1.050 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.61. Fulgent Genetics had a negative return on equity of 3.04% and a negative net margin of 58.03%. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $67.14 million. On average, analysts expect Fulgent Genetics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulgent Genetics Stock Performance

Fulgent Genetics stock opened at $20.35 on Wednesday. The company has a market cap of $608.47 million, a P/E ratio of -3.61 and a beta of 1.43. Fulgent Genetics has a one year low of $19.88 and a one year high of $44.09. The business has a fifty day moving average of $21.95 and a two-hundred day moving average of $25.06.

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their price objective on shares of Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating on the stock in a report on Wednesday, March 6th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.